HK Stock Market Move | JUNSHI BIO (01877) rose nearly 3%; its Tuoyi newly added indication was recently included in the national medical insurance catalog.

date
09:47 17/11/2026
avatar
GMT Eight
Junshi Bio (01877) rose nearly 3%, up 2.33% as of press time, at HK$14.49, with a turnover of HK$3.2936 million.
JUNSHI BIO (01877) rose nearly 3%, up 2.33% as of press time at HK$14.49, with a turnover of HK$3.2936 million. On the news front, on November 16, JUNSHI BIO issued an announcement that the indication of its product toripalimab injection (trade name: Tuoyi, product code: JS001) in combination with disitamab vedotin for HER2-expressing locally advanced or metastatic urothelial carcinoma was successfully included in the Class B scope of the "National Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance Drug Catalog (2026)" (hereinafter referred to as the "National Medical Insurance Catalog"). The new version of the National Medical Insurance Catalog will be officially implemented from January 1, 2027. As of the disclosure date of this announcement, all 13 indications of Tuoyi approved for marketing in mainland China have been included in the National Medical Insurance Catalog, making it the only anti-PD-1 monoclonal antibody drug in the catalog for the treatment of triple-negative breast cancer, melanoma, first-line renal cancer and first-line urothelial carcinoma. In terms of international layout, as of the disclosure date of this announcement, toripalimab has achieved a presence across six continents globally, having been approved for marketing in more than 50 countries and regions including China, the United States and Europe, with marketing applications submitted/accepted in multiple countries and regions.